Compare KYMR & WLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KYMR | WLK |
|---|---|---|
| Founded | 2015 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 10.3B |
| IPO Year | 2020 | 2004 |
| Metric | KYMR | WLK |
|---|---|---|
| Price | $121.83 | $77.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 26 | 15 |
| Target Price | ★ $107.72 | $106.87 |
| AVG Volume (30 Days) | 613.0K | ★ 1.2M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 1.90% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.70 |
| Revenue | $39,211,000.00 | ★ $11,170,000,000.00 |
| Revenue This Year | $10.61 | $5.51 |
| Revenue Next Year | $8.17 | $3.74 |
| P/E Ratio | ★ N/A | $111.43 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $39.84 | $56.33 |
| 52 Week High | $130.05 | $124.23 |
| Indicator | KYMR | WLK |
|---|---|---|
| Relative Strength Index (RSI) | 67.81 | 49.66 |
| Support Level | $76.40 | $70.80 |
| Resistance Level | $130.05 | $78.94 |
| Average True Range (ATR) | 4.22 | 2.95 |
| MACD | 1.29 | 0.48 |
| Stochastic Oscillator | 91.57 | 71.12 |
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Westlake is a forward-integrated commodity chemicals firm based in Houston. It began as a single low-density polyethylene plant and expanded its capabilities to include ethylene, vinyl chloride monomers, and polyvinyl chloride over the next two decades. The acquisition of Axiall in 2016 made it a North American leader in chlor-alkali and PVC. Today, Westlake has two defined segments: performance and essential materials, and housing and infrastructure products. The HIP segment began operating in 2022 following a series of acquisitions in the building products space. The firm aims to maximize the value of its chemical production by integrating with the HIP segment, realizing the higher margins of finished commercial goods.